Pacific Shuanglin Bio-pharmacy Co., Ltd.

Pacific Shuanglin Bio-Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company based in China, established in 1995 and listed on the Main Board of the Shenzhen Stock Exchange in 1996. The company specializes in the research, development, production, and sales of plasma-derived products, utilizing healthy human plasma and specifically immunized human plasma as raw materials. Its core products serve as critical national strategic reserves and essential medications for the emergency treatment of major diseases. The company is controlled by Gongqingcheng Shengbang Yinghao Investment Partnership and ultimately overseen by the State-owned Assets Supervision and Administration Commission of Shaanxi Provincial People’s Government. Pacific Shuanglin operates through two wholly owned subsidiaries: Guangdong Shuanglin Bio-Pharmaceutical Co., Ltd. and Harbin Pacific Bio-Pharmaceutical Co., Ltd. Guangdong Shuanglin is recognized as the largest high-tech plasma-derived product enterprise in Guangdong Province, while Pacific is the only such enterprise in Northeast China. The company has a total of 11 product varieties and operates 38 plasma collection stations nationwide, ranking among the top three in the industry. It emphasizes quality control and has established a comprehensive quality assurance system, while also focusing on expanding its product portfolio and enhancing research and development capabilities.

1.Good Level of Quality Control Product quality is the lifeline of a plasma-derived product enterprise and the cornerstone for building enterprise brands. The company has long adhered to the business philosophy of prioritizing quality and safety, placing great emphasis on the quality and safety management of its products. We strictly comply with legal regulations and quality management requirements in production and operations, ensuring all products exceed pharmacopoeia standards. The company maintains a comprehensive quality assurance system with full-process pharmaceutical quality and safety management mechanisms. We continuously enhance informatization and standardization capabilities to effectively guarantee the safety, stability, and efficacy of our products. Our wholly-owned subsidiary Guangdong Shuanglin Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as "Guangdong Shuanglin") has passed ISO 9001 Quality Management System certification and CNAS certification onsite review. Another subsidiary, Harbin Pacific Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as "Pacific"), has been awarded the Grade A Certificate of the Integration of Informatization and Industrialization Management System and recognized as a Heilongjiang Provincial Digital (Intelligent) Demonstration Workshop. Our robust quality management framework has established a solid foundation for the company's sustainable and healthy development. 2.Plasma Collection Scale Advantage According to the development logic and industry dynamics of plasme-derived product enterprises, a company’s scale is determined by its source plasma collection capacity. The company steadfastly implements a dual strategy of internal growth and external expansion. Guangdong Shuanglin, a national-level specialized and sophisticated "Little Giant" enterprise and the largest high-tech plasma-derived product enterprise in Guangdong Province, operates 19 plasma collection stations, with 17 currently active and 2 awaiting final inspection. Pacific (formerly known as Harbin Pacific Bio-Pharmaceutical Co., Ltd.), the only high-tech plasma-derived product enterprise in Northeast China with a full range of three major product categories and a provincial-level specialized and sophisticated enterprise, has 19 plasma collection stations, all of which have passed inspections and are fully operational. With 38 plasma collection stations in total, the company now ranks among the top three in the industry. In 2024, the company’s annual plasma collection volume exceeded 1,400 tons, solidifying its position in the first tier of plasme-derived product enterprises with over one thousand ton plasma capacity. 3.Product R&D Advantage According to the development logic and industry dynamics of plasma-derived product enterprises, the net profit per ton of plasma depends on new product development, with a greater variety of products leading to higher profitability. Guangdong Shuanglin offers 8 products across 3 categories with 18 specifications, while Pacific (formerly Harbin Pacific Bio-Pharmaceutical Co., Ltd.) provides 9 products across 3 categories with 31 specifications. Together, the company boasts 11 product varieties, ranking third in the industry (the highest number among domestic plasma-derived product enterprises is currently 14). The company possesses domestically leading R&D capabilities, with over 10 products in advanced stages of development. The product portfolio is expected to grow continuously, positioning the company among the industry leaders in terms of product diversity. Additionally, the company holds 62 authorized patents. Guangdong Shuanglin has established a Guangdong Provincial Doctoral Workstation, a Guangdong Provincial Science and Technology Expert Workstation, and a Guangdong Provincial Engineering Technology Research Center. Pacific operates a National Postdoctoral Workstation, the Heilongjiang Provincial Plasma-derived Product Engineering Technology Center, a Heilongjiang Provincial Technology Innovation Demonstration Enterprise, and a Heilongjiang Provincial Enterprise Technology Center. With its cutting-edge R&D expertise, the company will continue to strengthen its core competitiveness in the plasma-derived product sector. 4.Brand Effect Advantage Both Guangdong Shuanglin and Pacific (formerly Harbin Pacific Bio-Pharmaceutical Co., Ltd.) possess over two decades of experience in the production and sales of plasma-derived products. Strictly adhering to relevant laws and regulations, the companies prioritize quality as their foundation, consistently upholding the business philosophy of "quality first" and fulfilling their social responsibility to "provide safe medicines for the public." Through years of delivering safe, stable, and high-quality products, they have earned widespread recognition and trust from clients. The "Shuanglin" and "Pacific" brands have established a strong reputation in the industry for safety and excellence, creating significant brand influence. Additionally, the company’s comprehensive range of products and specifications enhances its competitive edge in overseas exports. Moving forward, through multi-brand strategies, optimized resource integration, and continued brand-building efforts, the company will further amplify its brand synergy and market advantage. 5.Management Team Advantage The company actively implements a "talent-driven development strategy", strengthening its leadership team through internal cultivation and external recruitment. Core members of the management team possess extensive industry expertise and proven professional capabilities, with deep experience in R&D, production, quality control, sales, and management within the plasma-derived product sector. They also demonstrate strong proficiency in capital operations, along with the ability to anticipate industry trends, adapt to market demands, and execute strategic resource integration and external expansions during industry transformations. The management team’s structure aligns seamlessly with the company’s strategic development plan, effectively driving dual growth through organic initiatives and external expansions. This ensures the realization of strategic goals and long-term vision, continuously creating value for shareholders and society.